Pricing is only one aspect that may vary sharply between exchange and non-exchange products: there is already considerable pressure on exchange products to shrink their provider networks and covered drug lists. I've become interested in Assurant Health, an insurer that decided to boycott the exchanges. Its prices for a Bronze plan are slightly higher than those of Blue Cross, but its network is the old-fashioned universal sort. The article cites to a detailed brief on risk pools, including this explanation of why network shrinkage may be a more powerful cost-control issue than I realized:
Prohibiting [denial of coverage for pre-existing conditions] leaves insurers vulnerable to attracting a disproportionate share of patients with poor health risks. This vulnerability might cause them to leave the market or encourage them to use more covert or indirect means of risk avoidance, such as selective marketing or structuring their provider networks to exclude the doctors or hospitals preferred by higher risk patients.It's not just that excellent hospitals like the Mayo Clinic or cancer centers charge high rates. It's that they attract exactly the sort of patient that an insurer needs to avoid if it can't tie its prices to the health status of brand-new customers.